One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi

Cecilia Kanyama, S. F. Molloy, Adrienne K. Chan, Duncan Lupiya, Chimwemwe Chawinga, Jack Adams, Philip Bright, David Lalloo, Robert S. Heyderman, Olivier Lortholary, Shabbar Jaffar, Angela Loyse, Joep J. Van Oosterhout, Mina C. Hosseinipour, Thomas S. Harrison

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

In Malawi, 236 participants from the ACTA cryptococcal meningitis treatment trial were followed-up for 12 months. The trial outcomes reported at 10 weeks were sustained to 1 year. One-week amphotericinB plus flucytosine was associated with the lowest 1 year mortality (27.5% [95%CI: 16.3 to 44.1]).

Original languageEnglish
Pages (from-to)521-524
Number of pages4
JournalClinical Infectious Diseases
Volume70
Issue number3
Early online date1 Jun 2019
DOIs
Publication statusPublished - 1 Feb 2020

Keywords

  • Cryptococcal meningitis
  • HIV
  • Long-Term follow-up
  • Malawi
  • Treatment

Fingerprint

Dive into the research topics of 'One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi'. Together they form a unique fingerprint.

Cite this